A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world.
Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company announced that it would invest over $500 million in the development of biopharmaceuticals through its sister company, Alvotech.
Alvogen operates three regional hubs with manufacturing and R&D capabilities in the U.S., South Korea and Romania. Alvogen's lines of business include: product development, contract manufacturing and research (CMO), and sales of generic and brand medicines, biosimilars and OTC’s.
Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information throughout the lifecycle of each product.
Alvogen has commercial operations in more than 30 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.
Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Connect with local teams to learn more about product offering in your region.